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1759Safety and Efﬁcacy of Stent Retrievers for the
Management of Acute Ischemic Stroke
Comprehensive Review and Meta-AnalysisABSTRACTOBJECTIVES This study sought to evaluate the safety and efﬁcacy of stent retriever for the management of acute
ischemic stroke.
BACKGROUND Stroke is the third leading cause of death and the most common cause of disability in the United States.
Early reperfusion has been associated with favorable outcomes. Stent retrievers are novel endovascular devices that
provide vessel recanalization via thrombus retrieval mechanical thrombectomy.
METHODS The authors performed a literature search using PubMed, EMBASE, and Cochrane Central Register of
Controlled Trials from May 2005 to May 2015. Randomized controlled trails (RCTs) comparing endovascular therapy
(ET) with the use of retrievable stents against standard therapy (ST) for the management of acute stroke were
included.
RESULTS Five RCTs (the MR CLEAN, ESCAPE, EXTEND-IA, SWIFT-PRIME, and REVASCAT studies) with 634 patients in
the ET group and 653 patients in the ST group met inclusion criteria. The frequency of a low 90-day modiﬁed Rankin
Score (0 to 2) in the intervention group was 42.6% compared with 26.1% in the control group (odds ratio: 2.43; 95%
conﬁdence interval [CI]: 1.9 to 3.09; p < 0.0001). The frequency of intracranial bleeding was 4.2% in the ET group
compared with 4.3% in the ST group (risk ratio: 1.08; 95% CI: 0.64 to 1.82; p ¼ 0.78). 90-day mortality was 15.1% in the
ET group compared with 18.7% in the ST group (risk ratio: 0.81; 95% CI: 0.58 to 1.12; p ¼ 0.19). There was no evidence of
signiﬁcant heterogeneity or publication bias for any of the endpoints.
CONCLUSIONS On the basis of the results of this meta-analysis of RCTs, ET with stent retrievers appears as a safe and
effective therapeutic option for acute ischemic strokedue to large vessel occlusion. (J AmColl Cardiol Intv 2015;8:1758–65)
© 2015 by the American College of Cardiology FoundationS troke is the third leading cause of death and themost common cause of disability in the UnitedStates (1). For acute ischemic stroke, early
reperfusion has been associated with favorable out-
comes (2). To date, intravenous thrombolysis within
4.5 h after the onset of acute stroke symptoms is the
most widely accepted strategy for prompt recanaliza-
tion (3). However, the narrow time window, the low
recanalization rates in patients with large vessel oc-
clusion and bleeding complications often limit its
use (4). Catheter-based therapies such as thromboem-
bolectomy, suction thrombectomy, angioplasty with
stenting, and stent retriever thrombectomy have
been tried in patients with acute ischemic stroke
alone or combined with intravenous or intra-arterial
thrombolysis with variable recanalization and clinical
outcomes (5,6). The best endovascular method has
not yet been reliably determined. Stent retrievers
(or retrievable stents) are endovascular devices that
provide vessel recanalization via thrombus-retrievalmechanical thrombectomy. They are deployed inside
the clot in order to envelop it within the stent struts.
Subsequently, the stent retriever with the entrapped
thrombus is pulled out of the artery. This mechanism
combines the high rates of prompt ﬂow restoration
with stenting and mechanical thrombectomy without
the risks of in-stent restenosis and thrombosis with
conventional stents (7). They have been successfully
used in recent acute stroke randomized controlled tri-
als (RCTs). In view of several recently published large
RCTs, the present meta-analysis seeks to systemati-
cally analyze the available evidence to evaluate the
safety and efﬁcacy of stent retriever therapy for the
management of acute ischemic stroke.
METHODS
A protocol was prospectively developed that detailed
the speciﬁc objectives, criteria for study selection,
approach to assess study quality, outcomes, and
ABBR EV I A T I ON S
AND ACRONYMS
IV = intravenous
NIHSS = National Institute of
Health Stroke Scale/Score
RCT = randomized controlled
trial
RR = risk ratio
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1760statistical methods. We performed a litera-
ture search using PubMed, EMBASE,
Cochrane Central Register of Controlled Tri-
als, and Internet-based sources of informa-
tion on clinical trials (ClinicalTrials.gov) from
May 2005 to May 2015. The Medical Subject
Heading (MeSH) terms “endovascular ther-
apy and ischemic stroke” and “intra-arterial
therapy and ischemic stroke” and “random-ized controlled trials” were used. No language re-
strictions were applied. Bibliographies of relevant
studies and the “Related Articles” link in PubMed
were used to identify additional studies. Published
abstracts from the annual meetings of the AmericanSEE PAGE 1766College of Cardiology, American Heart Associa-
tion, European Society of Cardiology, Trans Catheter
Therapeutics, Society of Coronary Angiography
and Intervention, and Euro Percutaneous Coronary
Revascularization, International Stroke Conference
were also identiﬁed. RCTs comparing the use of
retrievable stents with conventional therapy were
included in the meta-analysis. The ﬁnal search yiel-
ded 5 RCTs comparing stent retrievers with conven-
tional management of acute stroke (8–12).
DATA EXTRACTION. Two investigators (K.M. and
M.C.) independently reviewed the studies and re-
ported the results in a structured dataset. Studies
were evaluated carefully for duplicate or overlapping
data. Disparities between investigators regarding the
inclusion of each trial were resolved by consensus by
a third independent investigator (C.I.). Eligible trials
to be included in our meta-analysis had to meet the
following criteria: RCTs that compared the use of
endovascular therapy of acute stroke with the use of
retrievable stents against conventional therapy. Pre-
speciﬁed data elements were extracted from each
trial as follows: sample size, sex, age, baseline Na-
tional Institute of Health Stroke Scale/Score (NIHSS),
use of intravenous tissue plasminogen activator,
history of diabetes and atrial ﬁbrillation, 90-day
modiﬁed Rankin Score 0 to 2, symptomatic intracra-
nial hemorrhage, and 90-day mortality. Events from
each trial were recorded according to the intention-
to-treat principle. The primary endpoints were
“functional independence” deﬁned as low 90-day
modiﬁed Rankin Score 0 to 2, symptomatic intracra-
nial hemorrhage, and 90-day mortality.
STATISTICAL ANALYSIS. We used risk ratios (RRs)
with 95% conﬁdence intervals (CIs) as the metric of
choice for all outcomes. Categorical variables were
reported as percentages, and continuous variables asmean  SD. Weighted means were used for the
pooled estimates of continuous variables. The pooled
RRwas calculatedwith the DerSimonian-Lairdmethod
for random effects (13). For all the treatment effects
that were statistically signiﬁcant, we determined the
absolute risk reduction or the absolute risk increase,
and also the corresponding number needed to treat or
number needed to harm. To assess heterogeneity
across trials, we used the Cochran Q via a Mantel-
Haenszel test based on the pooled RR. Heterogeneity
was also assessed by means of the I2 statistic as pro-
posed by Higgins et al. (14) (determining the variance
across groups as a result of heterogeneity instead
of chance). Based on the I2 statistic, values of 25%,
50%, and 75% were considered as yielding low, mod-
erate, and high heterogeneity, respectively (13,15,16).
Results were considered statistically signiﬁcant at
p < 0.05. A funnel plot and the adjusted rank cor-
relation test were used to assess for publication bias
with respect to the primary outcome of interest.
With the use of a funnel plot, the RR was plotted on
a logarithmic scale against its corresponding stan-
dard for each study. In the absence of publication
bias, one would expect studies of all sizes to be
scattered equally right and left of the line showing
the pooled estimate of natural log RR. Begg’s
and the weighted regression test of Egger (p < 0.05)
were also used to assess a publication bias (17).
A post-hoc sensitivity analysis was planned in
case of signiﬁcant heterogeneity including studies
with similar outcome measures and mean follow-
up duration. Statistical analyses were performed
with RevMan software version 5.2.0 (Cochrane’s
Informatics & Knowledge Management Department)
and Comprehensive Meta-Analysis Software (Biostat,
Englewood, New Jersey).
RESULTS
Of the 1,988 citations found, 5 RCTs were identiﬁed.
Characteristics of the 5 RCTs are summarized in
Table 1 and Figure 1. All RCT studies were multicenter.
MR CLEAN (MR CLEAN: Endovascular Treatment for
Acute Ischemic Stroke in the Netherlands) and
REVASCAT (Endovascular Revascularization With
Solitaire Device Versus Best Medical Therapy in
Anterior Circulation Stroke Within 8 Hours) were
performed in a single country, EXTEND IA (Extending
the Time for Thrombolysis in Emergency Neurological
Deﬁcits—Intra-Arterial) in 2 countries, and SWIFT-
PRIME (Solitaire FR as Primary Treatment for Acute
Ischemic Stroke) and ESCAPE (Endovascular Treat-
ment for Small Core and Proximal Occlusion Ischemic
Stroke) were international. MR CLEAN included the
TABLE 1 Characteristics of the Randomized Controlled Trials
Study Name, Year Location n Comparison Primary Outcome
Use of Retrievable
Stents
MR CLEAN, 2015 Netherlands (16 centers) 500 Mechanical treatment, delivery of
a thrombolytic agent, or both
vs. conventional therapy
Modiﬁed Rankin Score at 90 days 97%
SWIFT-PRIME, 2015 International (90 centers) 196 IV t-PA þ Solitaire vs. IV
t-PA alone
Modiﬁed Rankin Score at 90 days 100%
EXTEND-IA, 2015 Australia and New Zealand
(14 centers)
70 Endovascular thrombectomy
with retrievable stent vs.
conventional therapy
Reperfusion at 24 h
Early neurologic improvement
($8-point reduction on the
NIHSS or a score of 0 or 1)
100%
ESCAPE, 2015 International (44 centers) 315 Mechanical treatment vs.
conventional therapy
Modiﬁed Rankin Score at 90 days 86.1%
REVASCAT,
2015
Spain (4 centers) 206 Endovascular thrombectomy
with retrievable stent vs.
conventional therapy
Modiﬁed Rankin Score at 90 days 100%
ESCAPE ¼ Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke; EXTEND-IA ¼ Extending the Time for Thrombolysis in Emergency Neurological Deﬁcits-Intra-
Arterial; IV ¼ intravenous; MR CLEAN ¼ MR CLEAN: Endovascular Treatment for Acute Ischemic Stroke in the Netherlands; NIHSS ¼ National Institute of Health Stroke Scale/Score;
REVASCAT ¼ Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours; SWIFT-PRIME ¼ Solitaire FR as Primary
Treatment for Acute Ischemic Stroke; t-PA ¼ tissue plasminogen activator.
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1761largest number of patients (500), followed by ESCAPE
(315). The primary outcome was 90-day modiﬁed
Rankin Score in MR CLEAN, SWIFT-PRIME, ESCAPE,
and REVASCAT, whereas in EXTEND-IA, the primary
outcome was reperfusion at 24 h and early neuro-
logical improvement ($8-point reduction on the
NIHSS or a score of 0 or 1). Three studies (SWIFT-
PRIME, EXTEND-IA, and REVASCAT) used exclusively
stent retrievers as their endovascular thrombectomy
device, whereas MR CLEAN and ESCAPE used retriev-
able stents in the majority of cases (97% and 86.1%,
respectively). The baseline age and sex characteristics
were comparable in all trials. In the EXTEND-IA study,
the baseline NIHSS Stroke Scalewas signiﬁcantly lower
in the conservative group compared with the inter-
vention group (13 vs. 16), whereas the percentage of
diabetic patients was higher (23% vs. 6%). SWIFT-
PRIME and ESCAPE included the higher number of
patients with known atrial ﬁbrillation (35% to 40%),
whereas ESCAPE had the highest percentage of dia-
betic patients (>20%). The baseline characteristics are
summarized in Table 2 and the clinical outcomes in
Table 3.
FUNCTIONAL OUTCOME. Rates of 90-day modiﬁed
Rankin Score were reported in all trials (Figure 2). The
overall frequency of functional independence (a low
90-day modiﬁed Rankin Score 0 to 2) in the
intervention group was 42.6% (293 of 634) compared
with 26.1% (171 of 653) in the control group. Patients
in the intervention group had an odds ratio of 2.43
(95% conﬁdence interval: 1.91 to 3.09; p < 0.0001) for
having a modiﬁed Ranking Score of 0 to 2 compared
with conventional therapy group. There was noevidence of statistical heterogeneity among studies
(I2 ¼ 0%; heterogeneity p ¼ 0.94) (number needed
to treat ¼ 6.25 patients). There was no evidence of
publication bias for this endpoint both on visual
estimation of the funnel plot and on Egger’s regres-
sion analysis (p ¼ 0.4).
INTRACRANIAL HEMORRHAGE. Rates of intracranial
bleeding were reported in all 5 trials. The overall
frequency of intracranial bleeding was 4.2% in the
intervention group (27 of 634) compared with
4.3% in the control group (28 of 652). The RR for
intracranial bleeding 1.08 (95% CI: 0.64 to 1.82;
p ¼ 0.78). There was no evidence of statistical
heterogeneity among studies (I2 ¼ 0%; heterogene-
ity p ¼ 0.63).
NINETY-DAY MORTALITY. Ninety-day mortality (Modi-
ﬁed Rankin Score 6) was reported in all trials. The
overall 90-day mortality was 15.1% in the interven-
tion group (96 of 634) compared with 18.7% in the
control group (122 of 653). The RR for 90-day mor-
tality was 0.81 (95% CI: 0.58 to 1.12; p ¼ 0.19) showing
a trend towards lower 90-day mortality that was not
statistically signiﬁcant. There was no evidence of
signiﬁcant statistical heterogeneity among studies
(I2 ¼ 29%; heterogeneity p ¼ 0.23).DISCUSSION
This meta-analysis of 5 most recent RCTs (MR CLEAN,
ESCAPE, EXTEND-IA, SWIFT-PRIME, and REVASCAT)
evaluating the addition of endovascular treatment
of ischemic stroke related to proximal intracranial
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FIGURE 1 Meta-Analysis Flow Diagram
RCT ¼ randomized controlled trial.
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1762arterial occlusion to conventional therapy (including
intravenous [IV] thrombolysis) demonstrates the
efﬁcacy of endovascular treatment in improving
functional outcomes and remarkable safety as de-
monstrated by no difference in rates of sym-
ptomatic intracranial hemorrhage compared with
standard therapy. Furthermore, there appears to be a
trend towards overall decreased 90-day mortality.
The infrequent convergence of 5 positive RCTs, even
after taking their differences into account, leads to the
apparently uncontestable assertion that there is
no longer equipoise in endovascular treatment of
ischemic stroke (18).
Similar outcomes were noted between the 4
studies that used some form of neuroimaging se-
lection (mismatch or core-infarct volume), compared
to the ﬁfth one (MR CLEAN study) that only required
demonstration of vessel occlusion. This solidiﬁes the
dictum that “time is brain”: endovascular treatment
is effective at the early stages of cerebral ischemia
due to large-vessel occlusion, whereas imaging se-
lection may identify patients with ischemic injury
that progresses slowly, and may thus be candidates
for treatment at extended time points. This was
also conﬁrmed in the DEFUSE-2 study (Diffusion
Weighted Imaging Evaluation for Understanding
Stroke Evolution Study-2) in which it was noted
that certain patients may have a slower rate of
TABLE 3 Clinical Outcomes of the Randomized Controlled Trials
Study Name, Year
90-Day Rankin 0-2 Symptomatic ICH Mortality 90 days
Intervention Control Intervention Control Intervention Control
MR CLEAN, 2015 32.6 19.1 7.7 6.4 21.0 22.0
SWIFT-PRIME,2015 60.0 35.0 0.0 3.0 9.0 12.0
EXTEND-IA, 2015 71.0 40.0 0.0 6.0 9.0 20.0
ESCAPE, 2015 53.0 29.0 3.6 2.7 10.4 19.0
REVASCAT, 2015 43.7% 28.2 1.9 1.9 18.4 15.5
Values are %.
ICH ¼ intracranial hemorrhage; other abbreviations as in Table 1.
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1763early diffusion-weighted imaging lesion growth, and
demonstrate improved outcomes after endovascular
treatment (19).
The aforementioned ﬁndings are in stark contrast to
the 3 previous reported studies in 2013 (20–22) that hadFIGURE 2 Forest Plot Meta-Analysis
Forest plot meta-analysis of the 5 RCTs on the frequency of 90-day mod
CI ¼ conﬁdence interval; M-H ¼ Mantel-Haenszel test; RCT ¼ randomizfailed to demonstrate a similar beneﬁt. Several
characteristics of the previous studies have been
proposed for this discrepancy: 1) prolonged onset-
to-treatment times; 2) low recanalization rates; 3)
insufﬁcient conﬁrmation of initial arterial occlusioniﬁed Rankin Score 0 to 2, intracranial bleeding, and 90-day mortality.
ed controlled trial.
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1764in a signiﬁcant percentage of patients; and 4) limited
use of current stent-retriever devices (23–25).
Despite the fact that these studies were technically
negative, they were, nevertheless, signiﬁcant be-
cause they failed to show worsening with endovas-
cular treatment and underscored the need for use
of modern retrieving devices and conﬁrmation of
large-vessel occlusion (26).
This meta-analysis conﬁrms that endovascular
treatment is effective in the treatment of acute
ischemic stroke due to large vessel occlusion in an
extended time window (up to 12 h), and regardless of
the use of additional neuroimaging criteria for selec-
tion, especially at earlier time points (up to 6 h). This
is an important breakthrough in stroke treatment, in
fact the most important breakthrough since the
NINDS (National Institute of Neurological Disorders
and Stroke) t-PA trial that established the use of IV
thrombolysis for ischemic stroke 20 years ago (27). It
is anticipated to result in major changes in health care
systems and accelerate the development of centers of
excellence, such as comprehensive stroke centers,
that will be preferentially able to accept and treat
patients with the most severe ischemic strokes (18).
Several current or planned studies (such as the DAWN
[Trevo and Medical Management versus Medical
Management Alone in Wakeup and Late Presenting
Strokes], PISTE [Pragmatic Ischaemic Stroke Throm-
bectomy Evaluation], THERAPY [Assess the Penum-
bra System in the Treatment of Acute Stroke],
THRACE [Trial and Cost Effectiveness Evaluation of
Intra-arterial Thrombectomy in Acute Ischemic
Stroke], and THRILL [Thrombectomy in Patients
Ineligible for IV tPA] studies) may provide high-level
evidence for the efﬁcacy of endovascular treatment in
different patient populations and subgroups. Further
advances are expected with the reﬁnement of
retrieving devices and selection criteria that may
allow the time window to be extended even further,
up to 15 h in the anticipated DEFUSE-3 trial, or even
up to 24 h in the DAWN trial (28,29). However, we
should keep in mind that the phenomenon of reper-
fusion injury will be a signiﬁcant factor that will
determine the success of endovascular treatment at
later time windows. Because up to one-third of stroke
patients arrive at the hospital within 8 h from stroke
onset, the expansion of the time window is likely to
remove a major roadblock for access to ischemic
stroke treatment and improve outcomes in this sig-
niﬁcant public health problem.
STUDY LIMITATIONS. There was heterogeneity in
the neuroimaging criteria for selection of patients:
The MR CLEAN study only required conﬁrmation oflarge-vessel occlusion, whereas the remaining 4
studies required selection of patients with sal-
vageable ischemic tissue. Regardless, all 5 studies
consistently required pre-treatment imaging conﬁr-
mation of large-vessel occlusion, in contrast to prior
RCTs. The 5 studies used different time points: Three
of the studies (MR CLEAN, EXTEND-IA, and SWIFT-
PRIME) treated patients up to 6 h from onset,
REVASCAT up to 8 h, and ESCAPE up to 12 h. It can be
said that these correspond to different stages of
acute ischemic injury, and are not immediately
comparable. However, the positive results provide
strong evidence that endovascular treatment is
effective at extended time windows (up to 6 h and
potentially up to 12 h). Future analyses and studies
will be required to better identify patients with
salvageable tissue within the time window of 6 to 12
h from stroke onset. Only the ESCAPE trial allowed
randomization of patients up to 12 h, and only 49
patients were randomized in that time window.
There was a trend towards improvement with
intervention, but the difference was not signiﬁcant.
Only 1 of the studies (MR CLEAN) was allowed to
proceed to the end of enrollment. Three of studies
were terminated after an unplanned interim analysis
(ESCAPE, EXTEND-IA, and SWIFT PRIME), whereas
the ﬁfth one (REVASCAT) was terminated after the
ﬁrst planned interim analysis. Even though the
interim conservative analyses demonstrated that
equipoise did not longer exist, and the respective data
and safety monitoring boards concluded that the
studies should be discontinued, it is possible that
the early termination is associated with a magniﬁca-
tion of the apparent treatment effect (30).
CONCLUSIONS
This meta-analysis of randomized clinical trials
demonstrates signiﬁcantly improved functional clin-
ical outcomes and a favorable safety proﬁle with
stent retriever endovascular therapy compared with
standard treatment alone, for the management of
acute stroke due to large-vessel occlusion (consis-
tently up to 6 h, and potentially up to 12 h), and
regardless of the use of additional neuroimaging
criteria for selection, especially at earlier time points
(up to 6 h).
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Konstantinos Marmagkiolis, Heart and Vascular Insti-
tute, Citizens Memorial Hospital, 1500 North Oakland
Road, Bolivar, Missouri 65613. E-mail: c.marmagiolis@
gmail.com.
PERSPECTIVES
WHAT IS KNOWN? For acute ischemic stroke, early reperfusion has
been associated with favorable outcomes. To date, intravenous
thrombolysis within 4.5 h after the onset of acute stroke symptoms is
themost widely accepted strategy for prompt recanalization. Catheter-
based therapies have been tried in patients with acute ischemic stroke
with variable recanalization and clinical outcomes; however, the best
endovascular method has not yet been reliably determined.
WHAT IS NEW? This meta-analysis evaluating the addition of
endovascular treatment of ischemic stroke related to proximal
intracranial arterial occlusion to conventional therapy (including IV
thrombolysis) demonstrates the efﬁcacy of endovascular treatment
with stent retrievers in improving functional outcomes and remark-
able safety compared to standard therapy. Furthermore, there ap-
pears to be a trend towards overall decreased 90-day mortality.
WHAT IS NEXT? This is an important breakthrough in stroke
treatment; in fact, the most important breakthrough since the NINDS
(National Institute of Neurological Disorders and Stroke) t-PA trial
that established the use of IV thrombolysis for ischemic stroke
20 years ago. It is anticipated to result in major changes in healthcare
systems and accelerate the development of centers of excellence,
such as comprehensive stroke centers, that will be preferentially
able to accept and treat patients with the most severe ischemic
strokes. Several current or planned studies may provide high-level
evidence for the efﬁcacy of endovascular treatment in different
patient populations and subgroups, reﬁnement of retrieving devices
and selection criteria that may allow the time window to be extended
even further.
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